Show simple item record

dc.contributor.authorPoikonen, Paula
dc.contributor.authorSjöström, Johanna
dc.contributor.authorKlaar, Sigrid
dc.contributor.authorNittby, Lena Tennvall
dc.contributor.authorSigurdsson, Helgi
dc.contributor.authorMadsen, Ebbe Lindegaard
dc.contributor.authorJoensuu, Heikki
dc.contributor.authorBlomqvist, Carl
dc.date.accessioned2007-11-13T10:52:42Z
dc.date.available2007-11-13T10:52:42Z
dc.date.issued2004-03-01
dc.date.submitted2007-11-13
dc.identifier.citationActa Oncol 2004, 43(2):190-5en
dc.identifier.issn0284-186X
dc.identifier.pmid15163169
dc.identifier.doi10.1080/02841860310022977
dc.identifier.urihttp://hdl.handle.net/2336/14520
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Link fielden
dc.description.abstractDocetaxel-related skin toxicity, oral and gastrointestinal mucosal toxicity, and changes in blood cell counts were investigated as predictive factors for major infections in 143 women treated with 3-weekly docetaxel (100 mg/m2) as second-line therapy for metastatic breast cancer in a randomized trial. Each patient with a major infection (n = 37) was compared with two controls. Skin toxicity (odds ratio 2.97, 95% CI 1.37-6.47), oral mucositis (1.98, CI 1.30-3.04), and the leukocyte nadir (0.12, CI 0.02-0.51) were significantly associated with a major infection in a univariate logistic regression analysis. In a multivariate analysis, skin toxicity was the only independent factor predictive for grade 3 to 4 infection (2.75, CI 1.00-7.58). A major infection was diagnosed in 62% (8 out of 13) of the docetaxel cycles in severely (grade 4) leukopenic patients who had grade 2 to 4 skin toxicity. Major infections are common in leukopenic patients who develop docetaxel-associated skin toxicity, and leukopenic patients presenting with docetaxel-induced skin toxicity may be candidates for prophylactic anti-infection measures such as prophylactic therapy with hematopoietic growth factors.
dc.language.isoenen
dc.publisherTaylor & Francisen
dc.relation.urlhttp://www.informaworld.com/10.1080/02841860310022977en
dc.subject.meshAntineoplastic Agents, Phytogenicen
dc.subject.meshBreast Neoplasmsen
dc.subject.meshClinical Trials, Phase IIIen
dc.subject.meshInfectionen
dc.subject.meshLeukocyte Counten
dc.subject.meshMouth Mucosaen
dc.subject.meshMucous Membraneen
dc.subject.meshNeutropeniaen
dc.subject.meshRegression Analysisen
dc.subject.meshSkinen
dc.subject.meshTaxoidsen
dc.titleSkin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxelen
dc.typeArticleen
dc.identifier.journalActa oncologica (Stockholm, Sweden)en
dc.format.digYES
html.description.abstractDocetaxel-related skin toxicity, oral and gastrointestinal mucosal toxicity, and changes in blood cell counts were investigated as predictive factors for major infections in 143 women treated with 3-weekly docetaxel (100 mg/m2) as second-line therapy for metastatic breast cancer in a randomized trial. Each patient with a major infection (n = 37) was compared with two controls. Skin toxicity (odds ratio 2.97, 95% CI 1.37-6.47), oral mucositis (1.98, CI 1.30-3.04), and the leukocyte nadir (0.12, CI 0.02-0.51) were significantly associated with a major infection in a univariate logistic regression analysis. In a multivariate analysis, skin toxicity was the only independent factor predictive for grade 3 to 4 infection (2.75, CI 1.00-7.58). A major infection was diagnosed in 62% (8 out of 13) of the docetaxel cycles in severely (grade 4) leukopenic patients who had grade 2 to 4 skin toxicity. Major infections are common in leukopenic patients who develop docetaxel-associated skin toxicity, and leukopenic patients presenting with docetaxel-induced skin toxicity may be candidates for prophylactic anti-infection measures such as prophylactic therapy with hematopoietic growth factors.


This item appears in the following Collection(s)

Show simple item record